Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

This study focused on the design, biometric simulation and optimization of an intracranial
nano-enabled scaffold device (NESD) for the site-specific delivery of dopamine (DA) as a …

Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although
poor delivery to the brain hinders their therapeutic application. In the current study, it is …

We are now in an aging population, so neurological disorders, particularly the
neurodegenerative diseases, are becoming more prevalent in society. As per the …

Due to limitations posed by the restrictive blood–brain barrier, conventional drug delivery
systems do not provide adequate cyto‐architecture restoration and connection patterns that …

Abstract Blood-Brain Barrier (BBB) acts as a highly impermeable barrier, presenting an
impediment to the crossing of most classical drugs targeted for neurodegenerative diseases …

The prevalence of neurological/neurodegenerative diseases, such as Alzheimer's disease is
known to be increasing due to an aging population and is anticipated to further grow in the …

Although effective symptomatic treatments for Parkinson's disease (PD) have been available
for some time, efficient and well-controlled drug delivery to the brain has proven to be …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the gradual loss
of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein …

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are
caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's …